Structure Therapeutics released Phase II results showing its oral GLP‑1 candidate aleniglipron achieved substantial weight loss at 44 weeks, with analyses characterizing the pill’s efficacy as competitive with injectable agents. Company data reported up to ~16% placebo‑adjusted weight loss and broad tolerability after dosing ramp‑up strategies reduced discontinuations. Structure plans to move the program into Phase III testing later this year. The readouts arrive amid intensified competition as multiple companies race to commercialize oral GLP‑1s and come while regulators and payers scrutinize safety and long‑term benefit profiles for the obesity market.